Thank you, Linda, and good morning, everyone.
later addition at sharing to INT-XXX moment that REGENERATE, want week. In PBC liver be a our data this outcomes meeting morning, to I we'll on take updates to and note starting this the new
Looking first at NASH.
diligently of our NASH. our resubmission mentioned, Jerry team liver due is fibrosis prepare As to to working and for OCA for NDA
the read in using again, XX biopsies the a for doses we FXR interim summer, XX X over As A panel response signals methodology, the and studied. consensus month planned was announced of effect for OCA other that agonism strong showed OCA also response antifibrotic the of analysis that rate was observed dose placebo. double the liver for milligrams
liver-related an with to strongest predictor of important we and people this NASH. can role be shown for reaffirms been Therefore, has fibrosis the due believe to living Fibrosis analysis morbidity new OCA mortality. play that
date of Safety of the during database in X,XXX examined considerations more running Phase trial the to the analysis patient FDA III years, longest mature raised XXXX deeply largest this space. safety and review and than been robust more have through
the FDA treatment X in been experts each events of hepatic it with by committee safety and a requested the the events, X analyzed MACE groups. cardiovascular events were The number the in committees. associated balanced. The set renal of adjudication reviewed cardiovascular have Core and balanced by major events
to biochemical generally rare Similarly, for reflected and vast and the NASH and showed OCA adjudicated events with renal milligrams, of due events a were of adjudicated numerically effects mild. XX common Hepatic patients are FXR majority a changes were events balanced. in higher fibrosis the number advanced agonism, that
all questions REGENERATE findings observed at well are raised prescribers. safety of the review a We manageable. oral gastroenterologists details Importantly, Ultimately, in late-breaking helps first and meeting. address other of additional as and experts, of our database a safety on and purview management to we longer and would types liver hepatic to the of efficacy both monitorable many target from the look that the believe in forward running both sharing within presentation the larger be events liver observed
our NASH fibrosis OCA patients risk With analysis hand, benefit in in of the to milligrams with is new strong. our that view is due it XX
is NDA an end the in we as Following spring advisory part the resubmission, anticipated by expect committee of of review process. the year, meeting which the X-month a
a the meet study, REVERSE reduction and we data the of stiffness that encouraged clinically in with evaluating patients Phase FibroScan result. compensated histology its cirrhosis safety showed not III significant liver the kilopascals, of a in efficacy endpoint, did While OCA to NASH were primary X due
new were for there no population addition, this patients. In in of OCA observed signals safety
cirrhosis in scientific data due conference. are be urgency Further and ongoing, progress analysis cirrhosis. an fibrosis with underscoring share clinical an endpoint patients and NASH the histology advanced high of compensated significance we bar proven data at has statistical trials, on to in extremely Achieving upcoming they to these before plan to REVERSE to intervene to
we've results planned resubmission that REVERSE, previously, REGENERATE to and FDA REVERSE very the for patient agency not will should REVERSE. is we populations. ready any Nevertheless, provide it. impacted X noted be the clear from enrolled by of As NDA our has ask been safety The different data
PBC. plans We've to evidence in Ocaliva wealth this Turning significant these support remain generating to progress quarter. We PBC. to real-world on of committed updates and made a
data a administered survival Gastroenterology, large X from the showed in patient improved journal, First, history transplant-free leading clinical compared published patients that natural trial data observed to for registries. Ocaliva
external improved study the treatment patients this transplant In in registry. the demonstrate risk lower confidence control with controlled death time had first an XX% either ultimate survival, to the transplant-free or PBC. patients cohorts follow-up therapy to is of strengthens of Ocaliva the our from This at that in liver these with consistent goal effect patient across X size Ocaliva any observations. treated publication, The is compared associated approximately relative during
OCA our for has IV this we'll the that rigorously COBALT, real-world with We're death, matched liver when liver These late-breaking presentation. of the A later Ocaliva pleased subjects other strong Starting with sharing OCA study with data the decreases been evidence control as-treated analysis of data external accepted and was controls. poster external at risk benefit from outcomes demonstrated week, decompensation. transplant COBALT Phase OCA comparing and a provide meeting. as be
PBC we'll and Komodo not who Second, a of are were compare patients U.S. Health, real-world leverages of from eligible, HEROES PBC group study the predefined group with sharing a with database, claims our clinical a in who were treated. but outcomes that patients Ocaliva, results comparable treated be U.S., who to detailed
shared line this reminder, a earlier data significant improvement receiving for survival in As were patients showed Ocaliva this in top study again, and, year from statistically event-free a PBC.
received than at group control death, any in or time for hospitalization individuals the Specifically, follow-up. XX% reduction decompensation a risk transplant Ocaliva of during liver of all-cause PBC at hepatic
is Europe for demonstrates The have accumulated of and from large clinical real-world far consistent PBC, we important know long-term thus transplant-free sets and and in evidence and the patients. benefits most to which the Ocaliva specifically U.K. compelling data goal around we survival, U.S., be the
regulatory data will support our for these to post-marketing be included in a submission of Ocaliva FDA fulfilling Ultimately, and PBC. requirements in
from In events real-world as study, be bring including addition the which our will submission anticipated evidence, by XXXX. of the Phase expert FDA, sNDA will IV to PBC our timing adjudication we requested into for COBALT,
through Ocaliva. with clinical We long-term and meeting our the with of patients PBC therapy remain committed to demonstrating post-marketing commitments working clinical closely benefits trials, our
our enroll different our bezafibrate is and on doses continue of our plus X PBC, fixed-dose evaluating long-standing Building of to Phase studies II we the OCA commitment combination to in components. patients ongoing,
living and Phase this benefits on on with combination sharing We next about provide III can remain year. individuals PBC that dose design and to study to updates our selection look excited the potential forward the
stage Turning now our to pipeline. earlier
study, week. agonist, Our We as FXR next-generation look our lead to as study updates our has Phase Phase sharing I at cohort. INT-XXX, to comprehensive next indication final our I liver on proof-of-concept meeting progressed study data and its from forward the our well for FRESH,
this I'll update. Andrew over turn for the our point, to Andrew? call financial At
